ALS | Parkinson's Disease | Cancer
Stroke | Alzheimer's Disease
a BLUE KNIGHT™ Company
A Robust Pipeline
of Disease Modifying
Medicines
PIPELINE
Target Overview - Lead Development Candidate Programs
ASHA-624
SARM1 in Axonal Degeneration
and Neuronal Cell Death
ASHA-624 is a novel molecular glue that inhibits SARM1-mediated axonal degeneration, restoring normal homeostasis.
DISEASE INDICATIONS
- Amyotrophic Lateral Sclerosis (ALS)
- Glaucoma
- Spinal Cord Injury
- Peripheral Neuropathies
ASHA-091
DRP-1 Mediated Mitochondrial
Hyper-Fragmentation
ASHA-091 is a first-in-class highly specific inhibitor of pathological DRP1 activation and restores normal mitochondrial homeostasis and function
DISEASE INDICATIONS
- Parkinson's Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Infectious Diseases & ME/CFS, Long COVID
- Ischemia/Reperfusion Injuries
ASHA-044
β-Catenin in Oncology
ASHA-044 is a breakthrough first-in-class UbiPRISM™ degrader targeting β-Catenin by establishing a synthetic destruction complex to restore normal β-Catenin signaling
DISEASE INDICATIONS
- Colorectal Cancer
- Heptaocellular Carcinoma
- Melonoma
© Copyright 2023 Asha Therapeutics, all rights reserved